Aptevo Therapeutics

50 articles with Aptevo Therapeutics

• Aptevo Therapeutics Announces the Launch of Its Second Platform Technology ADAPTIR-FLEX(TM) and Introduces the New Bispecific Prostate Cancer Candidate APVO442

  12/2/2020

  APVO442 is a Unique T-Cell Engager Designed to Target PSMA and CD3 for the Treatment of Prostate Cancer

• Aptevo Confirms Receipt of Unsolicited Indication of Interest

  11/19/2020

  Aptevo Therapeutics Inc. announced that it has received an unsolicited non-binding indication of interest from Tang Capital Partners, LP expressing its interest in acquiring all of the outstanding shares of Aptevo that it does not already own for $50.00 per share in cash.

• Aptevo Therapeutics and Alligator Bioscience Advancing the Bispecific 4-1BBx5T4 Antibody ALG.APV-527 Into Phase 1 Clinical Development

  11/16/2020

  Aptevo Therapeutics Inc. and Alligator Bioscience provided an update on ALG.APV-527, a novel immunotherapeutic bispecific candidate intended for the treatment of multiple solid tumors expressing 5T4, a tumor-restricted antigen.

• Aptevo Therapeutics Reports Third Quarter Financial Results and Provides Business Update

  11/10/2020

  Aptevo Therapeutics Inc. today reported financial results for the third quarter ended September 30, 2020, and provided a business update.

• Aptevo Therapeutics to Present at the Society for Immunotherapy of Cancer's (SITC) 35th Virtual Annual Meeting

  11/9/2020

  Aptevo Therapeutics Inc. announced that it will present two new posters at the Society for Immunotherapy of Cancer's 35th Virtual Annual Meeting, to be held from Monday, November 9, 2020 to Saturday, November 14, 2020.

• Aptevo Therapeutics Announces Second Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial

  11/9/2020

  Aptevo Therapeutics Inc., a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ platform, provided an update on its ongoing APVO436 Phase 1 clinical trial.

• Aptevo Therapeutics Adopts Limited Duration Stockholder Rights Plan

  11/8/2020

  Aptevo Therapeutics Inc. announced that its Board of Directors has approved the adoption of a limited duration stockholder rights plan and declared a dividend distribution of one right for each outstanding share of common stock.

• 

  Aptevo’s Phase I APVO436 Trial on Right Track Against AML

  11/3/2020

  Aptevo is a clinical-stage biotech company developing novel therapeutics built on its proprietary platform ADAPTIR™technology which is modular and includes bispecific molecules that recognize and bind to two unique target antigens simultaneously.

• Aptevo Therapeutics Announces First Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial

  11/3/2020

  Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary platform, today provided an update on its ongoing APVO436 Phase 1 clinical trial.

• Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial

  9/1/2020

  Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today provided an update on its ongoing APVO436 Phase 1/1b clinical trial

• Aptevo-Therapeutics-Reports-Second-Quarter-2020-Financial-Results

  8/14/2020

  Advances Phase 1/1b Clinical Trial of APVO436 for the Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Cohort 6 Enrollment Complete Presents New Preclinical Data Showing That ALG.APV-527 has Potential for a Favorable Safety Profile Extends Cash Runway into Q3 2021 Providing Runway Through Our Anticipated Clinical Data

• Aptevo Therapeutics Secures $25 Million Non-Dilutive Financing from Midcap Financial Trust

  8/6/2020

  Extends Cash Runway into Q3 2021 The Current Cash Balance is Anticipated to Create a Sufficient Timeline to Complete the APVO 436 Phase I(a) Dosing Cohorts Which Pre-Clinical Modelling Predicts May Deliver an Efficacious Dose

• Aptevo Therapeutics Engages Piper Sandler to Sell its RUXIENCE(R) and IXINITY(R) Royalty Streams & Milestones

  7/21/2020

  Aptevo Therapeutics has engaged Piper Sandler to sell its RUXIENCE® and IXINITY® royalty streams and milestone payments.

• Aptevo Therapeutics to receive Seven Year Quarterly Royalty Payment Stream from Pfizer for Sales of Rituximab Biosimilar

  6/26/2020

  Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today announced that it will receive a royalty from Pfizer related to sales of a rituximab biosimilar product, RUXIENCE® 

• Aptevo Therapeutics and Alligator Bioscience Present new Preclinical Data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit

  6/10/2020

  Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, and Alligator Bioscience AB (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy,

• Medexus Expands its US Product Portfolio by Acquiring the Hematology Asset IXINITY®

  2/28/2020

  Acquisition Expected to be Immediately Accretive to Adjusted EBITDA 1 Announces US$20 Million Credit Facility with MidCap Financial TORONTO and CHICAGO and MONTREAL, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“ Medexus ” or the “ Company ”) (TSXV: MDP, OTCQB: PDDPF) today announced that the Company, through its US-based subsidiary, acquired Aptevo BioTherapeutics LLC, a Delaware limited liability company owning the worldwide rights to the commercial hematology asset

• Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia

  12/6/2019

  Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to APVO436, a bispecific antibody candidate intended for the treatment of acute myelogenous leukemia (AML).

• Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting

  11/8/2019

  Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics and Alligator Bioscience AB (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy today announced that new preclinical data for ALG.APV-527 are being presented at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting at the National Harbor, Maryland, November 6-10, 2019.

• Aptevo Therapeutics Reports Third Quarter 2019 Financial Results

  11/7/2019

  Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today provided a business review and reported its financial results for the third quarter ended September 30, 2019.

• Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting

  11/9/2018

  Data Show That ALG.APV-527 Selectively Activates and Enhances Tumor-directed T-cell and Natural Killer (NK) Cell Responses